Skip to main content

Table 1 Characteristics of the asthma patients included in the study

From: Bronchial thermoplasty in asthma: an exploratory histopathological evaluation in distinct asthma endotypes/phenotypes

Parameters All patients (N = 30) Asthma endotypes/phenotypes
Eos ≥ 300/μl (N = 7) Eos < 300/μl (N = 23) P value* Atopy (N = 19) No Atopy (N = 11) P value* Allergy (N = 16) No allergy (N = 14) P value* Smoke exposure (N = 10) No smoke exposure (N = 20) P value*
Age, years, mean ± SEM 57.8 ± 2.9 50.1 ± 6.1 60.1 ± 3.1 0.128b 57.4 ± 3.9 58.4 ± 4.0 0.832b 53.5 ± 4.3 62.6 ± 3.3 0.176b 63.0 ± 1.9 55.2 ± 4.1 0.108b
Gender, Female/Male 19/11 5/2 14/9 1.000a 11/8 8/3 0.466a 12/4 7/7 0.257a 5/5 14/6 0.425a
BMI, mean ± SEM 27.8 ± 0.9 29.7 ± 2.7 27.2 ± 0.9 0.202b 27.4 ± 1.2 28.5 ± 1.4 0.714b 28.3 ± 1.4 27.2 ± 1.1 0.533b 28.4 ± 1.1 27.5 ± 1.3 0.644b
Pack Years, mean ± SEM 14.0 ± 4.2 8.3 ± 4.4 15.6 ± 5.1 0.653b 12.5 ± 5.5 16.8 ± 5.9 0.342b 16.3 ± 6.5 11.4 ± 4.7 0.622b 31.5 ± 8.5 4.3 ± 2.6  < 0.001b
Oral corticosteroids, n (%) 21 (70.0) 4 (57.1) 17 (73.9) 0.640a 13 (68.4) 8 (72.7) 1.000a 11 (68.8) 10 (71.4) 1.000a 7 (70.0) 14 (70.0) 1.000a
Oral corticosteroids, mg, mean ± SEM 13.8 ± 1.5 16.3 ± 5.5 13.2 ± 1.5 0.171b 14.4 ± 1.8 12.8 ± 2.9 0.453b 12.3 ± 2.4 15.5 ± 1.9 0.201b 12.5 ± 2.7 14.4 ± 1.9 0.511b
FEV1% of predicted value, mean ± SEM 66.9 ± 3.6 74.5 ± 6.1 64.6 ± 4.3 0.111b 68.0 ± 5.0 65.1 ± 4.9 0.863b 64.3 ± 4.6 69.9 ± 5.6 0.662b 62.8 ± 8.0 69.0 ± 3.7 0.281b
FVC % of predicted value, mean ± SEM 94.7 ± 3.5 93.3 ± 8.1 95.1 ± 3.9 0.713b 95.5 ± 4.5 93.3 ± 5.8 0.983b 92.4 ± 5.3 97.4 ± 4.4 0.506b 101.5 ± 4.9 91.3 ± 4.5 0.248b
FEV1/FVC, mean ± SEM 73.0 ± 3.2 84.2 ± 5.7 69.6 ± 3.6 0.042b 73.7 ± 4.5 71.8 ± 4.5 0.880b 72.5 ± 4.3 73.6 ± 5.0 0.835b 62.8 ± 6.0 78.1 ± 3.4 0.022b
RV % of predicted value, mean ± SEM 118.5 ± 6.8 103.8 ± 16.2 123.0 ± 7.4 0.249b 118.7 ± 9.8 118.2 ± 8.4 0.813b 123.7 ± 10.5 112.5 ± 8.5 0.480b 139.7 ± 11.2 107.9 ± 7.7 0.028b
TLC % of predicted value, mean ± SEM 104.3 ± 3.1 98.3 ± 8.5 106.1 ± 3.2 0.364b 105.0 ± 4.5 103.1 ± 3.8 0.651b 105.4 ± 4.6 103.0 ± 4.2 0.835b 116.3 ± 3.5 98.3 ± 3.7 0.007b
RV/TLC, mean ± SEM 108.6 ± 4.2 99.5 ± 8.9 111.4 ± 4.7 0.315b 106.1 ± 5.0 113.1 ± 7.5 0.621b 112.1 ± 6.5 104.7 ± 5.1 0.383b 112.6 ± 6.5 106.6 ± 5.4 0.481b
DLCO % of predicted value, mean ± SEM 89.1 ± 3.8 89.1 ± 7.6 89.2 ± 4.5 0.787b 88.8 ± 4.5 89.7 ± 7.2 0.813b 88.1 ± 5.5 90.4 ± 5.4 0.835b 87.8 ± 6.6 89.8 ± 4.8 0.538b
Reversibility FEV1%, mean ± SEM 12.0 ± 1.9 6.8 ± 2.0 13.6 ± 2.3 0.126b 11.5 ± 2.1 12.6 ± 3.5 0.859b 13.6 ± 2.5 10.4 ± 2.8 0.275b 10.2 ± 2.0 12.8 ± 2.6 0.601b
FeNO ppm, mean ± SEM 37.9 ± 5.9 53.1 ± 15.6 33.3 ± 5.9 0.169b 38.8 ± 7.2 36.4 ± 10.4 0.366b 36.4 ± 7.5 39.6 ± 9.5 0.803b 34.4 ± 8.2 39.7 ± 7.9 0.775b
IgE U/ml, mean ± SEM 349.5 ± 96.9 492.1 ± 129.5 306.1 ± 120.1 0.053b 524.4 ± 138.6 47.4 ± 7.5  < 0.001b 508.9 ± 170.1 167.4 ± 43.8 0.244b 388.7 ± 249.6 329.9 ± 81.8 0.692b
  1. *Comparisons were made by Fisher’s exact test (a) or by the Mann–Whitney test (b)
  2. SEM standard error of the mean, BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, TLC total lung capacity, RV residual volume, DLCO diffusing capacity for carbon monoxide, FeNO fractional exhaled NO, IgE immunoglobulin E, Eos eosinophils